View in EDS

Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α.

Saved in:

Bibliographic Details
Title:	Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α.
Authors:	Citro S; Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy. simona.citro@ieo.it., Bellini A; Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy., Miccolo C; Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy., Ghiani L; Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy., Carey TE; Department of Otolaryngology-Head and Neck Surgery, Department of Pharmacology, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA., Chiocca S; Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy. susanna.chiocca@ieo.it.
Source:	British journal of cancer [Br J Cancer] 2019 Mar; Vol. 120 (6), pp. 658-667. Date of Electronic Publication: 2019 Feb 15.
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1532-1827
DOI:	10.1038/s41416-019-0394-9